Impentri™ is a stable intravenous formulation of imatinib, an oral tyrosine kinase inhibitor used for the treatment of chronic myelogenous leukaemia and other rare cancers.
Impentri™ is a high impact product that is uniformly effective in a heterogeneous condition. The new treatment is based on the drug's ability to inhibit vascular leak, which drives the pulmonary oedema. It has proven effective in a number of human case reports as well as in vivo models.
ARDS currently lacks any approved pharmaceutical therapy, with treatment limited to supportive ventilatory care. As Impentri™ can significantly reduce the high mortality and incapacitating morbidities caused by ARDS, it will radically reduce the cost of care.Visit Impentri(TM) to learn more
Impentri™ is currently being advanced through human trials
Initially we evaluated the safety of imatinib in conditions similar to ARDS, involving a challenge test to human volunteers. Full details are available on the Clinicaltrials.gov website.
The second, Phase II trial has been conducted at sites across the Netherlands, to assess the effect of oral imatinib on patients with severe COVID-19 infection (CounterCOVID). Full protocol details are available on the EU Clinical trials register. The trial recently completed and the results published, showing a substantial benefit on mortality in these patients
A third, Phase II trial commenced in Q1 2021, to investigate IV imatinib (Impentri™) for the treatment of critically ill patients with COVID induced ARDS. This trial is being funded by the Innovative Medicines Initiative (IMI), and more details can be found at the Impentri website.